What are the treatments for small cell lung cancer with rubicatin (rubitin)? Clinical application and therapeutic effect

Lubicatin (Lurbinectedin) is a new type of anti-tumor drug mainly used to treat recurrent small cell lung cancer (SCLC). It is a transcription inhibitor that inhibits the transcription of DNA in tumor cells by targeting RNA polymerase II, thereby blocking the protein synthesis process of cancer cells. Clinically, rubicatin is mainly used for patients with small cell lung cancer who have relapsed after platinum-based chemotherapy, especially for patients with platinum-sensitive relapse, with good efficacy.

In terms of treatment options, rubicatin is usually used as a single agent and is administered intravenously. The recommended dose is 3.2 mg/m² once every 3 weeks. The injection time of this drug is approximately 1 hour. Before use, the patient's liver function and neutrophil levels need to be evaluated to determine whether it is suitable to continue treatment. For some patients, combination use with other chemotherapy drugs can also be considered, but currently the combination regimen is still in the research stage, and single drug is still the main method of routine usage.

Clinical studies (such as theATLANTIS trial) have shown that rubicatin has certain efficacy and safety in patients with recurrent small cell lung cancer. According to key clinical trial data before the US FDA approval, the median progression-free survival (PFS) of patients treated with rubicatin is approximately 3.5 months, the median overall survival (OS) can reach about 9 months, and some patients can also observe tumor shrinkage or even stable disease. In addition, the side effects of the drug mainly include bone marrow suppression (such as neutropenia), fatigue and nausea, and the overall tolerability is relatively controllable.

Overall, rubicatin provides a new treatment option for patients with recurrent small cell lung cancer, especially in response strategies after first-line treatment failure. As an anti-tumor drug with a unique mechanism of action, it complements the shortcomings of traditional platinum and topoisomerase inhibitors. However, in practical applications, doctors still need to make comprehensive judgments based on the patient's condition, treatment history, and physical condition to formulate individualized treatment plans to obtain better efficacy and fewer toxic and side effects.

Reference materials:https://www.zepzelca.com/